1. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐Hodgkin lymphomas. (27th June 2013) Authors: Hagemeister, Fredrick; Rodriguez, Maria Alma; Deitcher, Steven R.; Younes, Anas; Fayad, Luis; Goy, Andre; Dang, Nam H.; Forman, Arthur; McLaughlin, Peter; Medeiros, Leonard Jeffrey; Pro, Barbara; Romaguera, Jorge; Samaniego, Felipe; Silverman, Jeffrey A.; Sarris, Andreas; Cabanillas, Fernando Journal: British journal of haematology Issue: Volume 162:Number 5(2013:Sep.) Page Start: 631 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia. (17th August 2013) Authors: Silverman, Jeffrey A.; Reynolds, Laurie; Deitcher, Steven R. Journal: Journal of clinical pharmacology Issue: Volume 53:Number 11(2013:Nov.) Page Start: 1139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗